Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis
Metrics: PDF 576 views | HTML 1280 views | ?
Qiao-Hui Zhan1,*, Jian-Qin Fu1,*, Fang-Meng Fu1, Jie Zhang1 and Chuan Wang1
1Department of General Surgery, Fujian Medical University Union Hospital, Fujian Province, Fuzhou, China
*These authors contributed equally to this work and should be considered as co-first authors
Chuan Wang, email: email@example.com
Keywords: time; adjuvant chemotherapy; breast cancer; suvival; meta-analysis
Received: August 01, 2017 Accepted: November 17, 2017 Published: December 07, 2017
The relationship between survival and time to the start of adjuvant chemotherapy (AC) among breast cancer patients is unclear. In order to illustrate the effect of delaying the initiation of AC on survival we have undertaken a systematic review and meta-analysis.
We identified 12 available studies in the meta-analysis including 15 independent analytical groups. This meta-analysis showed that a 4-week delay before AC was associated with a significantly worse overall survival (OS)(HR=1.13; 95% confidence interval [CI], 1.08–1.19) and disease free survival (DFS)(HR=1.14; 95%CI, 1.05–1.24). Two studies categorized patients into hormone receptor-positive, ERBB2-positive, and triple-negative breast cancer (TNBC) patients according to the clinicopathological features of breast cancer. The HRs for OS between waiting time (WT) ≤30 days and 31–60 days in the subgroups were extracted and analyzed. The analysis demonstrated that a WT of 31–60 days was related to worse OS among patients with TNBC (HR, 1.26; 95% CI, 1.08–1.48), but had no significant effect on OS among those with hormone receptor-positive (HR, 1.02; 95% CI, 0.89–1.15) or ERBB2-postive (HR, 0.95; 95%CI, 0.79–1.14) tumors.
In this meta-analysis of the eligible literatures reviewing the time to AC, a longer waiting time to adjuvant chemotherapy may lead to worse survival in breast cancer patients, especially in TNBC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.